8-K: Humana Reaffirms 2024 Earnings Guidance at Investor Meetings

Humana reaffirms its 2024 earnings guidance of approximately $14.87 diluted EPS and $16.00 adjusted EPS during investor meetings.

Summary

• Humana's senior management is scheduled to meet with investors and analysts between March 5, 2024, and March 31, 2024.
• During these meetings, Humana intends to reaffirm its 2024 earnings guidance.
• The company projects diluted earnings per common share (EPS) of approximately $14.87 for the year ending December 31, 2024.
• Humana also projects adjusted earnings per common share (Adjusted EPS) of approximately $16.00 for the same period.
• This guidance is consistent with the guidance issued in Humana's press release dated January 25, 2024.
• Adjusted EPS is a non-GAAP financial measure used by management to assess core operating performance.
• The reconciliation of GAAP EPS to Adjusted EPS includes adjustments for amortization of identifiable intangibles, the impact of exiting the employer group commercial medical products business, and the cumulative net tax impact of non-GAAP adjustments.

Sentiment

Score: 7

Explanation: The sentiment is positive as the company is reaffirming its guidance, which is a sign of stability and confidence. However, the document also includes a cautionary statement about forward-looking statements, which slightly tempers the positive sentiment.

Positives

• Humana is reaffirming its previously issued earnings guidance, indicating stability in their financial outlook.
• The company is actively engaging with investors and analysts, demonstrating transparency.
• Management is using adjusted EPS as a consistent indicator of core business operations, which can provide a clearer picture of performance.

Risks

• The document includes a cautionary statement about forward-looking statements, noting they are subject to risks, uncertainties, and assumptions.
• The company's performance is subject to risks outlined in their SEC filings.

Future Outlook

Humana reaffirms its 2024 earnings guidance, projecting approximately $14.87 in diluted EPS and $16.00 in adjusted EPS.

Management Comments

• Management believes that Adjusted EPS, when presented with GAAP EPS, provides a comprehensive perspective to more accurately compare and analyze the Company's core operating performance over time.
• Management uses Adjusted EPS as a consistent and uniform indicator of the Company's core business operations, as well as for planning and decision-making purposes and in determination of incentive compensation.

Industry Context

This announcement is typical for companies engaging with investors and analysts, providing reassurance about financial performance and outlook. It is common for healthcare companies to use non-GAAP measures like adjusted EPS to highlight core operational performance.

Comparison to Industry Standards

• Humana's reaffirmation of its earnings guidance is a standard practice among publicly traded companies, particularly in the healthcare sector, to maintain investor confidence.
• Other large health insurance companies like UnitedHealth Group (UNH) and CVS Health (CVS) also provide regular earnings guidance and often use adjusted metrics to present a clearer picture of their operational performance.
• The use of adjusted EPS is common in the industry to account for non-recurring items and provide a more consistent view of underlying profitability, similar to how other companies in the sector present their financial results.

Stakeholder Impact

• Shareholders will likely view the reaffirmation of earnings guidance positively.
• Analysts will use this information to update their models and recommendations.
• The company's employees may feel more secure knowing the company is on track with its financial goals.

Next Steps

• Humana's management will continue to meet with investors and analysts between March 5, 2024, and March 31, 2024.
• The company will likely provide further updates on its financial performance in future reports.

Key Dates

Keywords

earnings guidance, EPS, adjusted EPS, investor relations, financial performance, non-GAAP, Humana, healthcare